Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma

Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma

Abstract Purpose There are limited and no standard therapies for recurrent glioblastoma. We herein report the antitumour activity and safety of sintilimab, bevacizumab and temozolomide (TMZ) in recurrent glioblastoma. Methods We retrospectively analysed eight patients with recurrent glioblastoma tre...

Full description

Bibliographic Details
Main Authors: Yinghao Lu, Limin Liao, Kunpeng Du, Jianhua Mo, Xia Zou, Junxian Liang, Jiahui Chen, Wenwen Tang, Liwei Su, Jieping Wu, Junde Zhang, Yujing Tan
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Recurrent glioblastoma
Immunotherapy
Sintilimab
Treatment outcomes
Online Access:https://doi.org/10.1186/s12885-024-11848-z

Internet

https://doi.org/10.1186/s12885-024-11848-z

Similar Items